Skip Navigation LinksHome > Explorations > Grants Awarded

 Grand Challenges Explorations Grants

Grand Challenges Explorations fosters creative projects that show great promise to improve the health of people in the developing world. Initial grants are awarded two times a year, and successful projects have the opportunity to receive additional funding of up to $1 million.

On May 10, 2010, the Gates Foundation announced that 78 new global health projects received Grand Challenges Explorations grants. Learn more about these below. Round 5 grants will be announced in October 2010.

To review all 340 Explorations projects, select "Show All Rounds" in the Round drop-down menu.

 Find Awarded Grants By

Topic
Technologies
Round
Showing Grants 1 to 10 of 20
A Novel Vaccination Strategy for Cutaneous Leishmaniasis
Primary Investigator:
Shaden Kamhawi, National Institutes of Health, Bethesda, MD, United States - US
Topic:
Round:
Round 2 – May 2009

Because Leishmania is transmitted to humans when sand flies feed on humans, Shaden Kamhawi of the National Institutes of Health in the U.S. proposes to develop a novel vaccine against salivary proteins of sand flies with the aim to induce a strong immune response against the parasite.

Adjuvant Effects of a Special Light
Primary Investigator:
Mei Wu, General Hospital/Harvard Medical School, Boston, MA, United States - US
Topic:
Round:
Round 2 – May 2009
Laser light at a specific setting can activate antigen presenting cells in the skin and temporarily make cellular membranes permeable. Mei X. Wu and colleagues at Massachusetts General Hospital/Harvard Medical School in the U.S. will test whether injection of a vaccine into laser-exposed skin can significantly enhance immune responses stimulated by the vaccine.
An Altruistic Vaccine for Mosquito Transmitted Pathogens
Primary Investigator:
Paul Young, University of Queensland, Brisbane, Queensland, Australia - AU
Topic:
Round:
Round 2 – May 2009
Mosquito transmitted pathogens such as dengue and malaria are a significant disease burden on the world’s population. Paul Young of the University of Queensland in Australia aims to develop a novel vaccine approach that is based on blocking mosquito transmission of these disease agents rather than inducing pathogen-specific immunity.
Capturing Nature’s Weapons to Prevent Infectious Diseases
Primary Investigator:
Gregory Tew, University of Massachusetts, Amherst, MA, United States - US
Topic:
Round:
Round 2 – May 2009
To better understand the role that antimicrobial peptides play in the immune system, Gregory Tew of the University of Massachusetts Amherst in the U.S. will test synthetic molecules that mimic these peptides for their ability to clear bacteria by engaging the innate and adaptive immune system.
Customized Insecticides for Combating Disease Vectors
Primary Investigator:
John Abrams, University of Texas Southwestern Medical Center, Dallas, TX, United States - US
Topic:
Round:
Round 2 – May 2009
John Abrams of the University of Texas Southwestern Medical Center in the U.S. will utilize novel mutagenesis and selection strategies to develop new variants of the Cry protein, a toxin producing the pathogen Bt, in an effort to create customized insecticides that can selectively target disease vectors without harming humans and non-target species.
Generation of Influenza-Resistant Chicken by Triple Combination Lentiviral Vector-mediated Genetic Modification
Primary Investigator:
Chen Yangchao, Chinese University of Hong Kong, Hong Kong, China - CN
Topic:
Round:
Round 2 – May 2009

Chen Yangchao of the Chinese University of Hong Kong proposes developing a lentiviral vector that targets the entry and replication of influenza viruses in domestic chickens. The team plans to test the ability of these modified chickens to be resistant to various influenza viruses in an effort to reduce the frequency of flu epidemics in poultry and, ultimately, in humans.

Human Polyomavirus BKV as a HIV Vaccine Vector
Primary Investigator:
Simon Lacey, Beckman Research Institute of the City of Hope, CA, United States - US
Topic:
Round:
Round 2 – May 2009

BK virus is a very common and non-pathogenic virus that persists in specific organs for long periods of time. Simon Lacey of Beckman Research Institute of the City of Hope in the U.S. proposes using an engineered BK virus as a vaccine vector to introduce HIV polyepitope sequences in hopes of inducing a strong and long-lasting immune response against HIV.

Increasing Vaccination Efficacy with ACE Inhibitors
Primary Investigator:
Julio Scharfstein, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil - BR
Topic:
Round:
Round 2 – May 2009

Julio Scharfstein of Universidade Federal do Rio de Janeiro in Brazil will study whether a pre-dose of captopril, an established ACE inhibitor and anti-hypertension drug, can also increase the potency of vaccines by increasing activation of dendritic cells.

Inhibition of Octopamine Biosynthesis in Invertebrates
Primary Investigator:
Mark Alkema, University of Massachusetts, Worchester, MA, United States - US
Topic:
Round:
Round 2 – May 2009
The neurotransmitter octopamine is unique to the invertebrate nervous system and plays a crucial role in invertebrate behavior and fertility. Mark Alkema of the University of Massachusetts in the U.S. will attempt to design drugs to disrupt the biosynthesis of octopamine as a new strategy to interfere with the lifecycle of invertebrate parasites.
Large-Scale MHC Epitope Analysis for Vaccine Development
Primary Investigator:
Gustavo Fioravanti Vieira, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil - BR
Topic:
Round:
Round 2 – May 2009

Gustavo Fioravanti Vieira of Universidade Federal do Rio Grande do Sul in Brazil will create 3-D computer models of viral epitopes anchored to different alleles of MHC molecules to search for “generalist” epitopes that can be used to develop viral vaccines that are effective against a broad spectrum of pathogens. 

1 - 10 Next

 How to Apply

 Map of Grants